Research shows neonatal stem cells could be used as treatment for Crohn’s disease

Betsy Goodfellow | July 31, 2023 | News story | Research and Development Crohn’s disease, Gastrointestinal tract, Stem cells, gastrointestinal 

Recent studies from the Ann & Robert H Lurie Children’s Hospital in Chicago have discovered that human neonatal cardiac-derived mesenchymal stem cells can induce wound-healing and reduce inflammation in the digestive system, caused by Crohn’s disease.

The researchers used a mouse model to trial the potential treatment and found that injecting the cells into the inflammatory lesions was a successful method of administration. However, this requires surgical procedures; in order for this treatment to be used officially with humans, researchers would have to develop a safer way for the cells to be received. Doctors intend to inject the stem cells through a vein in the arm, although more animal trials will be necessary before clinical trials can begin.

While alternative treatments for Crohn’s disease are available, such as various medication or surgeries for the digestive system, the neonatal mesenchymal stem cells would avoid the severe side effects that typically come with the medication, such as gastrointestinal dysfunction.

Arun Sharma, PhD, from the Stanley Manne Children’s Research Institute, commented: “Our results are encouraging and definitely provide a new platform to potentially treat aspects of chronic inflammatory bowel diseases”. He confirmed that the goal is to “utilise cell type as treatment and as a preventive measure before symptoms can develop”, and is sure that the “potential is enormous”.

Researchers on the project believe these cells could be used as possible treatment for other inflammatory diseases and are excited for what this development could mean for the future.

Rebecca Lee

Related Content


Bone regeneration stem cell “putty” sees positive results in trials

Belgian clinical stage company, Novadip Biosciences, has announced positive results from its Phase I trial …

Rinri Therapeutics secures £3.2 million grant for hearing loss therapy

Sheffield-based biotech company, Rinri Therapeutics, have secured a £3.2 million grant from Innovate UK to …


Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic …

Latest content